, Nov. 11, 2010
/PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB) ("the Company"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announced that Huifeng CEO Jing'an Wang, will make a presentation at the 2010 Maxim Group Growth Conference to be held on November 18, 2010
at the Grand Hyatt Hotel in New York, NY
. The Company presentation details are provided below:
Date: November 18, 2010
Presentation time: 9:00 am -9:30 am
Location: Edison/Palace of Grand Hyatt New York
The 4th annual Maxim Group Growth Conference is a senior level, interactive conference experience designed to meet the needs of our institutional clients. It combines company presentations, break-out sessions and management 1-on-1 meetings to assist clients with gaining an in-depth perspective on the issues affecting the growth of presenting companies.
This one-day event will feature more than 80 presentations across six designated tracks from a diverse selection of both domestic and international companies. For more information about the conference and registration, please visit http://www.maximgrp.com/growthconf/index.php
To request a one-on-one meeting or to be added to Huifeng's email list, please contact Kevin Fickle at Kevin@nuwagroup.com or call 415-332-7200.
To be added to the Company's email distribution for future news releases, please send your request to Kevin@nuwagroup.com.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the Company's web site at: http://www.hfgb.cn/
For more information, please contact:
Mr. Kevin Fickle
Huifeng Bio-Pharmaceutical Technology, Inc.
Ms. Bing He
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.